NEW YORK, March 22 (Reuters) – The business model of Valeant Pharmaceuticals International Inc, target of a securities investigation and under scrutiny for its pricing and accounting practices, “was…
The post Janus’ Gross says Valeant based on leverage, financial engineering appeared first on NASDAQ.